Cuộc họp báo cáo kết quả kinh doanh Quý 2/2026 của MediWound (MDWD): VALU đi đúng tiến độ, tái khẳng định dự báo
Doanh thu Quý 2/2026 của MediWound đã giảm xuống còn 3,1 triệu USD trong khi việc tuyển mộ bệnh nhân cho nghiên cứu VALU vẫn đi đúng kế hoạch và ban lãnh đạo tái khẳng định dự báo doanh thu ở mức 24 triệu - 26 triệu USD.
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.